Liao et al. identified an ATP-competitive inhibitor of PGK1, DC-PGKI (ethyl 6,7-dichloro-3-(4-((4-(piperazin-1-yl)phenyl)carbamoyl) piperazin-1-yl) quinoxaline-2-carboxylate), through a high-throughput screening platform (IC50 value; 0.16 μM) in lung cancer cells [79]. The gene discussed is PGK1; the disease is lung carcinoma.